Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL

Ann Hematol. 2001:80 Suppl 3:B77-83. doi: 10.1007/pl00022796.
No abstract available

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Female
  • Germany
  • Humans
  • Immunotherapy
  • International Cooperation
  • Lymphoma, Non-Hodgkin / classification
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / mortality
  • Lymphoma, Non-Hodgkin / pathology
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Prognosis
  • Radiotherapy, Adjuvant
  • Remission Induction
  • Risk Factors
  • Rituximab
  • Severity of Illness Index
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol